Rigel Pharmaceuticals (RIGL) Cash from Investing Activities (2010 - 2026)

Rigel Pharmaceuticals has reported Cash from Investing Activities for 17 years, with the latest figure at -$8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 24.42% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$89.8 million (down 1233.16% YoY), and the FY2025 full-year result was -$92.4 million, down 2336.44% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$8.0 million, up from -$25.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $22.6 million in Q1 2022, with the low at -$33.2 million in Q3 2025.
• Average Cash from Investing Activities over 5 years is -$1.6 million, with a median of $313000.0 recorded in 2024.
• Year-over-year, Cash from Investing Activities soared 424.96% in 2024 and plunged 3471.25% in 2025.
• Tracing RIGL's Cash from Investing Activities over 5 years: stood at $18.6 million in 2022, then plunged by 136.96% to -$6.9 million in 2023, then slumped by 58.77% to -$10.9 million in 2024, then slumped by 132.38% to -$25.4 million in 2025, then jumped by 68.56% to -$8.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$8.0 million (Q1 2026), -$25.4 million (Q4 2025), and -$33.2 million (Q3 2025), per Business Quant data.

Peer Comparison